Evidence map›Paper›PMID 32035059›Full record

ArticleThe American journal of pathology2020

A Role of the Heme Degradation Pathway in Shaping Prostate Inflammatory Responses and Lipid Metabolism.

Lisa Vikström Lilljebjörn, Eva Csizmadia, Andreas Hedblom, Giacomo Canesin, Alireza Kalbasi, Mailin Li, Farah Kramer, Karin E Bornfeldt, Barbara Wegiel

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lisa Vikström LilljebjörnDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Eva CsizmadiaDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Andreas HedblomDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Giacomo CanesinDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Alireza KalbasiDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Mailin LiDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Farah KramerDepartment of Medicine, Division of Metabolism, Endocrinology, and Nutrition, UW Medicine Diabetes Institute, Seattle, Washington.
Karin E BornfeldtDepartment of Medicine, Division of Metabolism, Endocrinology, and Nutrition, UW Medicine Diabetes Institute, Seattle, Washington; Department of Pathology, University of Washington School of Medicine, Seattle, Washington.
Barbara WegielDivision of Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Cancer Research Institute, Boston, Massachusetts. Electronic address: bwegiel@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USUniversity of Washington · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Role of Serum Amyloid A in Diabetic Vascular DiseaseP01HL092969 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E. · 2008 to 2019
$23.5M
Role of biliverdin reductase during sterile inflammation in the liver.R01DK104714 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEGIEL, BARBARA · 2016 to 2020
$2.0M
Heme degradation pathway and immunomodulation in prostate cancer.R21CA169904 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEGIEL, BARBARA · 2013 to 2014
$411k
NCI NIH HHS R21 CA169904NHLBI NIH HHS P01 HL092969NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK104714
6 · The paper itself

Abstract

The molecular mechanisms of prostate inflammation are unclear. We hypothesized that heme oxygenase 1 (HMOX1; HO-1), an enzyme responsible for degradation of heme to carbon monoxide, bilirubin, and iron, is an important regulator of inflammation and epithelial responses in the prostate. Injection of non-uropathogenic Escherichia coli (MG1655 strain) or phosphate-buffered saline into the urethra of mice led to increased numbers of CD45

Indexed as

AnimalsBilirubinCarbon MonoxideCell ProliferationCoenzyme A LigasesEscherichia coliEscherichia coli InfectionsHemeHeme Oxygenase-1InflammationInterleukin-1betaLipid MetabolismMacrophagesMaleMembrane ProteinsMiceACSL1 protein, mouseBilirubinCarbon MonoxideCoenzyme A LigasesHemeHeme Oxygenase-1Hmox1 protein, mouseIL1B protein, mouseInterleukin-1betaMembrane Proteins

Identifiers

PMID32035059
PMCPMC7217330
OpenAlexW3004433533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.